NASDAQ:BMRN
$88.49
(
-0.276%
)
Friday, 26th May 2023
BioMarin Pharmaceutical Inc. Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $87.81 | $97.42 | Friday, 26th May 2023 BMRN stock ended at $88.49. This is 0.276% less than the trading day before Thursday, 25th May 2023. During the day the stock fluctuated 1.50% from a day low at $88.48 to a day high of $89.81. |
| 90 days | $87.34 | $103.58 | |
| 52 weeks | $70.73 | $117.77 |
Historical BioMarin Pharmaceutical Inc. prices
| Date | Open | High | Low | Close | Volume |
| 2016-06-15 | $81.40 | $85.53 | $81.31 | $84.01 | 1 906 419 |
| 2016-06-14 | $80.22 | $82.66 | $79.55 | $81.05 | 1 139 954 |
| 2016-06-13 | $81.09 | $83.98 | $79.50 | $80.11 | 1 253 187 |
| 2016-06-10 | $82.35 | $82.48 | $79.52 | $81.10 | 1 080 173 |
| 2016-06-09 | $83.75 | $84.61 | $82.71 | $82.94 | 891 547 |
| 2016-06-08 | $85.36 | $85.64 | $83.04 | $84.10 | 1 021 090 |
| 2016-06-07 | $88.64 | $89.30 | $85.23 | $85.50 | 1 178 323 |
| 2016-06-06 | $89.14 | $90.05 | $87.21 | $89.52 | 721 862 |
| 2016-06-03 | $91.15 | $91.49 | $88.02 | $90.00 | 1 107 650 |
| 2016-06-02 | $87.17 | $92.48 | $87.17 | $91.52 | 1 950 583 |
| 2016-06-01 | $88.69 | $88.90 | $86.01 | $87.40 | 1 285 718 |
| 2016-05-31 | $89.35 | $91.25 | $88.94 | $89.65 | 1 370 934 |
| 2016-05-27 | $87.57 | $89.22 | $86.41 | $89.09 | 846 254 |
| 2016-05-26 | $88.04 | $88.39 | $86.21 | $87.26 | 861 628 |
| 2016-05-25 | $88.31 | $89.85 | $87.50 | $88.81 | 1 062 649 |
| 2016-05-24 | $86.32 | $88.88 | $86.16 | $87.95 | 911 752 |
| 2016-05-23 | $86.85 | $88.15 | $85.35 | $85.51 | 831 160 |
| 2016-05-20 | $84.94 | $86.63 | $84.34 | $86.45 | 869 066 |
| 2016-05-19 | $86.46 | $87.44 | $83.40 | $84.75 | 865 197 |
| 2016-05-18 | $83.54 | $87.51 | $83.21 | $87.16 | 1 186 155 |
| 2016-05-17 | $85.73 | $87.50 | $82.89 | $84.05 | 1 567 254 |
| 2016-05-16 | $82.82 | $86.80 | $82.82 | $86.47 | 1 072 121 |
| 2016-05-13 | $79.79 | $84.39 | $79.79 | $82.71 | 1 359 916 |
| 2016-05-12 | $82.51 | $83.02 | $78.20 | $79.79 | 987 733 |
| 2016-05-11 | $87.24 | $87.24 | $82.09 | $82.22 | 893 941 |
| 2016-05-10 | $84.55 | $87.62 | $82.73 | $87.37 | 1 430 851 |
| 2016-05-09 | $81.10 | $85.06 | $80.57 | $83.98 | 1 035 433 |
| 2016-05-06 | $80.36 | $82.35 | $79.40 | $80.80 | 794 303 |
| 2016-05-05 | $82.16 | $82.63 | $79.32 | $80.74 | 1 073 214 |
| 2016-05-04 | $84.15 | $84.74 | $81.72 | $82.14 | 1 512 358 |
| 2016-05-03 | $86.00 | $87.41 | $84.91 | $85.09 | 1 012 384 |
| 2016-05-02 | $85.71 | $86.98 | $83.92 | $86.90 | 1 112 123 |
| 2016-04-29 | $83.44 | $87.50 | $83.02 | $84.68 | 1 704 163 |
| 2016-04-28 | $86.95 | $87.38 | $84.60 | $85.10 | 1 472 249 |
| 2016-04-27 | $88.11 | $88.61 | $86.22 | $87.72 | 1 010 314 |
| 2016-04-26 | $90.07 | $91.00 | $86.73 | $88.71 | 1 225 745 |
| 2016-04-25 | $93.76 | $93.76 | $89.80 | $90.22 | 1 741 149 |
| 2016-04-22 | $91.98 | $94.08 | $89.68 | $93.80 | 2 545 553 |
| 2016-04-21 | $89.25 | $92.05 | $85.50 | $91.99 | 2 120 163 |
| 2016-04-20 | $92.00 | $92.81 | $88.00 | $89.31 | 3 908 451 |
| 2016-04-19 | $87.26 | $88.25 | $85.32 | $86.37 | 1 709 176 |
| 2016-04-18 | $86.09 | $87.16 | $83.90 | $87.00 | 1 191 715 |
| 2016-04-15 | $89.61 | $89.61 | $85.04 | $86.75 | 1 550 486 |
| 2016-04-14 | $89.93 | $89.98 | $88.02 | $88.85 | 1 421 029 |
| 2016-04-13 | $85.00 | $88.64 | $85.00 | $88.52 | 1 732 435 |
| 2016-04-12 | $83.03 | $85.39 | $82.26 | $85.00 | 1 235 718 |
| 2016-04-11 | $85.58 | $86.28 | $82.67 | $83.20 | 1 145 644 |
| 2016-04-08 | $88.77 | $89.35 | $84.02 | $85.21 | 1 393 106 |
| 2016-04-07 | $89.00 | $91.91 | $86.66 | $87.79 | 1 810 635 |
| 2016-04-06 | $83.01 | $89.43 | $82.95 | $89.34 | 1 820 683 |
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
